Compass Group PLC Sponsored ADR (CMPGY)
Compass Pathways: The Bull Case Is Early, Not Wrong
COMPASS Pathways plc is developing pharmaceutical-grade psilocybin treatments for severe mental health conditions, notably treatment-resistant depression. CMPS remains a pipeline-stage biotech with no current sales, as its lead product, COMP360, is still in clinical trials. A recent executive order aims to accelerate access to psychedelic drug research and treatments, potentially benefiting CMPS's regulatory pathway.
Compass: Clarity Is Lacking, But I'm Bullish Anyway
Compass, Inc. remains a Buy following its transformative merger with Anywhere Real Estate, despite recent underperformance versus the S&P 500. COMP's pro forma EBITDA could reach $643.4M, or up to $868.4M with full $225M in expected cost synergies, making valuation compelling. Net debt has risen to $2.25B post-merger, but improved cash flow and scale from new brands and services support the investment thesis.
Rocket's AI Push and Compass Deal Could Shift Mortgage Share
RKT bets on AI, servicing scale and a Compass deal to drive mortgage share gains, but execution risks and housing headwinds cloud timing.
Compass Diversified's $292M Sale Ignites Stock
Compass Diversified's recent divestiture provides the company with substantial capital to significantly reduce its debt and improve its overall financial flexibility.
Compass Minerals Redeems 2027 Notes to Transform Balance Sheet
CMP plans to redeem $150M in 2027 notes on March 30, aiming to deleverage and strengthen its balance sheet with available liquidity.
Compass: Highly Profitable And Worth Buying
Compass (COMP) remains a buy as it outpaces industry growth and leverages the Anywhere Real Estate acquisition. COMP trades at a de-risked entry point, with a 10.3x EV/FY26 adjusted EBITDA multiple and strong margin improvement prospects. Q1 revenue guidance of $2.55–$2.75B implies 88–102% y/y growth, driven by M&A and expanding post-transaction services.
MSCI Acquires Compass Financial to Expand Multi-Asset Indexes
MSCI buys Compass Financial Technologies to strengthen multi-asset index capabilities spanning equities, commodities and digital assets while expanding its analytics reach.
Compass, Inc. (COMP) Q4 2025 Earnings Call Transcript
Compass, Inc. (COMP) Q4 2025 Earnings Call Transcript
Compass, Inc. (COMP) Reports Q4 Loss, Tops Revenue Estimates
Compass, Inc. (COMP) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
Compass, Inc. (COMP) Expected to Beat Earnings Estimates: Should You Buy?
Compass (COMP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Compass Pathways' depression treatment meets main goal in late‑stage study
Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.
